TianGang Yinuo Secures Tens of Millions in Pre-A+ Financing Round Led by Hefei Industrial Investment with Follow-on Investment from CAS Star

This time, tens of millions of pre-The successful completion of the A+ round financing not only marks that TGI has continued to make significant progress in the fields of TCE, NKCE, immune checkpoint antibodies, and immune cytokine drug research and development, but also provides strong financial support for accelerating the clinical transformation of related drugs. This fully demonstrates the recognition by investment institutions of TGI's innovative technology in the field of immunotherapy and their confidence in the company’s future development.。

"TGI" Focuses on the SourceInnovation, focusing on breakthroughs in transformative technologies, is committed to the exploration and application of cutting-edge technologies, continuously launching new products and technologies with independent intellectual property rights, and occupying the innovative source of the pharmaceutical industry chain. The company has independently developed the ABC-NKer® platform and the low-toxicity CD3 bispecific antibody platform, facilitating the development of TCE, NKCE, immune checkpoint antibodies, and immune cytokine products.

Based on a series of globally novel targets discovered independently, we have developed more than 10 product series across four major categories, all of which are either global first-in-class or best-in-class."TGI"Currently, there are three products.(Project Code: TGI-2, TGI-5, TGI-6)Obtained the approval from the U.S. Food and Drug Administration (FDA) （FDA）, National Medical Products Administration of China（NMPA）Clinical Trial Approval: TGI-6 has respectively initiated Phase I clinical trials at Beijing Cancer Hospital and Shandong Cancer Hospital. To date, the first four dose-escalation cohorts have been successfully completed, with favorable and controllable safety data observed in subjects.

Academician of the Chinese Academy of Engineering & Academician of the European Academy of Sciences,"TGI"Founder Professor Tian Zhigang said: "After three years of hard work,"TGI"Has laid out a rich product pipeline, and it is proceeding as expected. Thank you very much for your continued support and attention."TGI"The investment institutions have firmly supported us during the capital winter, which is not only a high recognition of TGI, but also an expectation for China's innovative drugs. The success of this pre-A+ round of financing will provide us with more sufficient financial support to accelerate the R&D and clinical transformation of core pipeline drugs. We will continue to focus on breakthroughs in core technologies, speed up the enrichment and upgrading of our product lines, and commit ourselves to developing original immunotherapy technologies and drugs, bringing more and better tumor immunotherapy drugs to patients."